Study on bioequivalence of gefitinib tablets in healthy Chinese subjects

doi:10.12092/j.issn.1009-2501.2019.11.010

Abstract

Abstract:

AIM: To evaluate the bioequivalence of two preparations of gefitinib tablets in healthy Chinese subjects. METHODS: This study was a randomized, open-label, double-period, single-center clinical trial after a single-dose oral administration of 250 mg, 56 subjects were divided into groups of fasting bioequivalence study and postprandial bioequivalence study. The blood concentrations of gefitinib tablets in plasma at different time after drug administration were determined by HPLC-MS/MS. The pharmacokinetic parameters were calculated and analyzed statistically with non compartment model method. RESULTS:The main pharmacokinetic parameters of test and reference(27 subjects) of gefitinib tablets administered fasted were as follows: t1/2 were（20.8±8.3）and（21.5±9.7）h, tmax were（5.63±1.82）and（5.30±1.44）h, Cmax were（200±86）and（203±84）ng/mL, AUC0-t were（4 968±2 268）and（4 853±2 073）ng·h/mL, AUC0-∞ were（5 054±2 325），（4 950±2 111）ng·h/mL, the relative bioavailability calculated by AUC0-tand AUC0-∞were 104.4% and 103.9%, respectively; The main pharmacokinetic parameters of test and reference(28 subjects) of gefitinib tablets administered with food were as follows: t1/2 were（21.1±9.9）and（22.0±10.1）h；tmax were（4.46±2.22）and（4.46±1.82）h；Cmax were（299±106）and（304±119）ng/mL；AUC0-t were（6 700±3 142）and（6 594±3 004 ）ng·h/mL；AUC0-∞ were（6 846±3 265），（6 750±3 136）ng·h/mL , the relative bioavailability calculated by AUC0-t and AUC0-∞ were 101.1% and 100.9%, respectively. CONCLUSION: The two gefitinib tablets administered fasted or with food were bioequivalent in healthy Chinese subjects.

Key words: gefitinib, healthy volunteers, bioequivalence, HPLC-MS/MS

CLC Number:

R969

WANG Mengyao,HUANG Jie, LIU Yanan, YANG Shuang, WU Shuting, YANG Xiaoyan, YE Ling, GUO Can, HUANG Zhijun. Study on bioequivalence of gefitinib tablets in healthy Chinese subjects[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1275-1280.

References

［1］Kazandjian D, Blumenthal GM, Yuan W, et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer［J］. Clin Cancer Res, 2016, 22(6): 1307-1312.
［2］Cataldo VD, Gibbons DL, Perez-Soler R, et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib［J］. N Engl J Med, 2011, 364(10): 947-955.
［3］芮益芳. 药价“国家谈判”启动外资药企或以降价换市场［J］. 中国外资, 2016, (9): 64-65.
［4］岳媛. 中国肿瘤医疗市场将进入黄金十年(下)［N］. 医药经济报，2016-12-19(F02).
［5］Wong AL, Xiang X, Ong PS, et al. A review on liquid chromatography-tandem mass spectrometry methods for rapid quantification of oncology drugs［J］. Pharmaceutics, 2018, 10(4):221.
［6］冯晓杰，杜丽英，冯章英，等. LC-MS/MS法测定人血药浓度的基质效应研究进展［J］. 中国新药杂志, 2015, 24(13): 1488-1492, 1497.
［7］U.S. Food and Drug Administration. Draft guidance on gefitinib［EB/OL］.(2017-07)［2019-04］. http:www.accessdata.fda.gov/scripts/cder/psg/index.cfm?event=Home.Letter&searchLetter=G#letterSearchBar.pdf.
［8］Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetic studies of gefitinib ［J］. Clin Pharmacokinet, 2005, 44(11): 1165-1177.
［9］Zhang H, Li Q, Zhu X, et al. Association of variability and pharmacogenomics with bioequivalence of gefitinib in healthy male subjects［J］. Front Pharmacol, 2018, 9: 849.
［10］Bergman E, Forsell P, Persson EM, et al. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors ［J］. Int J Pharm, 2007, 341(1/2): 134-142.
［11］Tang W, Tomkinson H, Masson E, et al. Effect of sustained elevated gastric pH levels on gefitinib exposure ［J］. Clin Pharmacol Drug Dev, 2007, 6(5):517-523.
［12］Swaisland HC, Cantarini MV, Fuhr R, et al. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics ［J］. Clin Pharmacokinet, 2006, 45(6): 633-644.
［13］Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers ［J］. Clin Pharmacokinet, 2001, 40(4): 297-306.
［14］Cantarini MV, McFarquhar T, Smith RP, et al. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers ［J］. Clin Ther, 2004, 26(10): 1630-1636.
［15］Rawluk J, Waller CF. Gefitinib［J］. Recent Results Cancer Res, 2018, 211: 235-246.
［16］陈羽中，沈波，等. EGFR敏感突变晚期非小细胞肺癌的靶向治疗进展［J］. 临床肿瘤学杂志, 2019，24(5): 454-462.

[1]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[2]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[3]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[4]	GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
[5]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[6]	SHI Gexin, CHONG Rui, HE Kun, WU Haitang, ZHOU Yu, DUN Zhongjun, WEN Qing, ZHANG Jiguo, ZHANG Rong. A fully replicated crossover bioequivalence study of mycophenolate mofetil capsules in Chinese healthy male subjects under fasting and fed conditions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1255-1263.
[7]	GAO Rong, MA Yazhong, ZHAO Haixia, WANG Zhaoyuan, ZHANG Weihong, YUAN Hailong. Bioequivalence of amlodipine besylate tablets in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 56-62.
[8]	HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69.
[9]	CAI Mingmin, SHAO Jing, TANG Lu, SUN Qiuyue, DOU Ting, QIAN Wei, WANG Huiping. Bioequivalence study of buthlphthalide injection in Chinese healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 70-76.
[10]	ZHENG Binjie, LIU Na, ZENG Xiangchang, HUANG Xinyi, CHEN Lulu, OU-YANG Dongsheng. Effects of gut microbiota on pharmacokinetics and its consideration in the evaluation of the consistency of quality and efficacy of generic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 662-671.
[11]	SUN Yuchen, LIU Yinhui, ZHANG Xian, YUAN Tong, JING Mengyao, ZAHNG Xinyu, YANG Jin. Exploration of screening criteria for healthy volunteers in human bioequivalence clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 714-720.
[12]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[13]	LI Xiaomin, JIN Hao, ZHOU Wenzhi, YANG Hanyue, ZOU Ting, GUO Jie, XU Pingsheng. Bioequivalence of metformin hydrochloride sustained-release tablets in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 408-413.
[14]	WANG Hui, CUI Chang, YANG Shuang, YAO An, WU Shuting, YANG Xiaoyan, YE Ling, ZOU Zhi, TANG Zhi, YANG Guoping, HUANG Jie, OUYANG Dongsheng. Bioequivalence of solifenacin succinate tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 299-304.
[15]	WANG Xiaoru, ZHANG Xueyuan, WANG Xiaoyan, YANG Hanyu. Bioequivalence study of pramipexole hydrochloride tablets in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 190-195.